Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2026-01-21 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing the granting of a Japanese patent for their drug 'masitinib' in the treatment of progressive multiple sclerosis. It details the patent number, the implications for intellectual property, the clinical study background (AB07002 and MAXIMS), and the competitive positioning of the drug. As this is a corporate announcement regarding regulatory/intellectual property developments and does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2026-01-21 French
AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des donn
Earnings Release Classification · 1% confidence The document is a press release from AB Science announcing positive clinical trial results (Phase 1) for their drug candidate AB8939 in combination with venetoclax for treating acute myeloid leukemia (AML). It details patient response rates, clinical trial methodology, market potential, and intellectual property status. This type of announcement regarding clinical trial progress and efficacy data is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement of material information that does not fit into more specific categories like earnings releases or annual reports. FY 2026
2026-01-07 French
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
Investor Presentation Classification · 1% confidence The document is a press release from AB Science detailing clinical trial results (Phase 1) for their drug candidate AB8939. It provides specific efficacy data, safety profiles, and future development plans for a pharmaceutical product. This type of document, which provides detailed updates on clinical research and development progress, is classified as an Investor Presentation or corporate update regarding R&D, which falls under the 'Investor Presentation' (IP) category in this schema as it serves to inform investors about the company's pipeline and market potential.
2026-01-07 English
Le brevet pour le masitinib dans le traitement de la drépanocyose a été officiellement accordé aux Etats-Unis avec une protection jusqu'en 2040
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing the granting of a US patent for their drug 'masitinib' in the treatment of sickle cell disease. It details the scientific rationale, the clinical trial status (Phase 2), and the strategic importance of this intellectual property. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a corporate announcement regarding business operations and intellectual property, it falls under the general regulatory filing category.
2025-12-22 French
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing the formal grant of a US patent for their drug 'masitinib' in the treatment of sickle cell disease. It provides details on the patent, the medical rationale, and the status of clinical trials. This type of corporate announcement regarding product development, intellectual property, and clinical progress is classified as a general regulatory filing or corporate announcement, which falls under the 'RNS' (Regulatory Filings) category as it does not fit into specific financial reporting or governance categories.
2025-12-22 English
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
Regulatory Filings Classification · 1% confidence The document is a press release announcing that an external investment bank (Maxim Group) has initiated research coverage on AB Science. It summarizes the analyst's buy recommendation and target price. Since this is a general corporate announcement regarding analyst coverage and does not fit into specific categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.